Please assess the completion status of the following clinical trial:

Trial Title: A Quality of Life Study of Peginterferon-Alfa-2a Plus Ribavirin in Participants With Chronic Hepatitis C and Persistently Normal Alanine Transaminase (ALT) Levels

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Serological confirmation of chronic infection by anti-hepatitis C virus (HCV) assay~* HCV ribonucleic acid (RNA) positive~* CHC with normal transaminases~* Compensated liver disease~* Non-pregnant and willing to use two contraceptive methods (if fertile)~* At least 4 weeks of prior treatment with peginterferon alfa-2a and ribavirin~Exclusion Criteria:~* Pregnant or lactating women~* Co-infection with hepatitis A or B, or human immunodeficiency virus (HIV)~* History of seizures or depression~* History of autoimmune disease, severe heart or lung disease, or renal failure with reduced creatinine clearance~* Uncontrolled thyroid disease~* Severe retinopathy~* Leukopenia or thrombocytopenia~* Bleeding esophageal varices or other evidence of hepatic decompensation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chronic Hepatitis C Participants (Type: None): Participants with chronic hepatitis C, who were under treatment with peg-interferon alfa-2a and ribavirin for four weeks, will be observed up to 24 weeks after end of treatment (EOT) (up to 72 weeks). Peg-interferon alfa-2a and ribavirin will be administered as per treating physician discretion and according to summary of product characteristics.

Based on this trial design, predict the completion outcome and termination type (if applicable).